Jump to content
This site uses cookies. Continued use is acceptance of our Terms of Use and Privacy Policy. More Info... ×
  • Welcome to Celiac.com!

    You have found your celiac tribe! Join us and ask questions in our forum, share your story, and connect with others.




  • Celiac.com Sponsor (A1):



    Celiac.com Sponsor (A1-M):


  • Get Celiac.com Updates:
    Help Celiac.com:
    eNewsletter
    Donate
  • Record is Archived

    This article is now archived and is closed to further replies.

    Roy Jamron
    Roy Jamron

    Synthetic Stool May Advance Fecal Transplant Therapy for Celiac Disease

    Reviewed and edited by a celiac disease expert.
    Synthetic Stool May Advance Fecal Transplant Therapy for Celiac Disease - Photo: CC--INEEDCoffee.com
    Caption: Photo: CC--INEEDCoffee.com

    Celiac.com 02/02/2013 - The possible link between the makeup of gut bacteria and celiac has been a subject of past discussion in "More Evidence Links Gut Bacteria to Celiac Disease"[1] and other articles.  Certain gut bacteria appear to enhance the immune response to gluten which may contribute to the onset of celiac disease.  Vitamin D may reduce or eliminate this enhanced gluten response, and, therefore, vitamin D deficiency may be a significant factor contributing to the onset and development of celiac disease.[2]  "Fecal transplantation", probiotics, and vitamin D have been advocated as possible therapy, treatment, and/or preventative measures against celiac disease.  While vitamin D and probiotics may have potential as preventative measures against the onset of celiac disease early in life, the option of a fecal transplant provides the actual possibility of restoring tolerance to gluten or curing celiac disease later in life following long-term intestinal mucosal recovery on a gluten-free diet.  In particular, fecal transplantation might make it possible to treat refractory celiac disease which does not respond to a gluten-free diet.

    Fecal transplant therapy for gastrointestinal disorders was pioneered by the world reknown Australian gastroenterologist, Prof. Thomas J. Borody, M.D., and is now used most successfully for treatment of persistant C. difficile infections of the gastrointestinal tract.  Fecal transplantation involves the actual transfer of screened and filtered fecal material from a healthy donor into the gut of a patient, previously treated with antibiotics to clear gut bacteria, replacing the patient's own gut bacteria with a healthy mix of donor gut bacteria.  The fecal material may be administered either orally or anally, via tubes.  Selecting and screening a healthy donor, usually a spouse or close relative, as well as the "disgust" factor have limited use of this therapy in past years, but its high anecdotal success rate for treating stubborn C. difficile cases is finally bringing fecal transplantation into the mainsteam of routine gastrointestinal practice.  The first clinical trial of fecal transplant therapy involving 43 C. difficile patients compared to conventional vancomycin antibiotic therapy has just been published finding fecal transplantation 3 times more effective than vancomycin in resolving C. difficile infections.[3,4]

    Celiac.com Sponsor (A12):
    To date, there does not appear any record of an attempt or clinical trial to treat celiac disease via fecal transplant therapy.  A big problem preventing any significant clinical trial of fecal transplantation for celiac disease is there is no way to "standardize" the healthy donor fecal material.  The mix of bacteria from every donor is unique.  Each donor must also undergo careful screening for harmful fecal pathogens.  But, now, recent developments may make such a clinical trial feasible.  A synthetic stool substitute was successfully used to clear C. difficile infections in 2 patients as part of a "proof-of-principle" study which may lead the way to eliminate the need for individual healthy feces donors and the need for screening tests.  The synthetic stool consisted of a mix of 33 bacteria species isolated from the stool of one healthy donor and cultured under simulated intestinal conditions.[5,6]  Such a standardized synthetic stool potentially administered orally in capsule form could make large scale fecal transplantation clinical trials possible.  An "off-the-shelf" bacteria mixture specifically developed for the treatment of celiac disease might become a reality.

    In the case of refractory celiac disease, a gluten-free diet does not stop the continued destruction of the intestinal mucosa.  Research has not yet found the reason for refractory celiac disease, but "molecular mimicry" may be one possible cause.  Celiac disease is an immune response to particular sequences of amino acids in gluten peptides called epitopes.  In the absence of gluten, if there exist peptides from other sources with amino acid sequences matching or "mimicking" these gluten epitopes, the destructive immune response may continue to damage the mucosa.  This is molecular mimicry in action.  It is possible that some gut bacteria may express some of these epitopes on their surface, or, more likely, secrete peptides that contain these epitopes.  These bacterial secretions might then coat the lining of the intestine sustaining the immune response.  Secreted epitopes are the more likely cause of refractory celiac disease than bacteria surface epitopes because the immune system would eventually destroy the bacteria if bacteria surface epitopes were involved.  But if the cause were the bacterial secretion epitopes, the bacteria itself would not be attacked and would continue to produce the secretions indefinitely perpetuating the mucosal damage.  Fecal transplant therapy might cure refractory celiac disease by eliminating the gut bacteria producing the epitope mimicking secretions.  How likely are such gut bacteria molecular mimics to exist?  One study has investigated this for the case of multiple sclerosis and concluded there is a strong likelihood that "normally occurring gut bacterium" could produce epitopes that might cause MS through molecular mimicry.[7]  One case of molcular mimicry between human peptides and wheat peptides has been found.[8]

    In the case of normal celiac disease (non-refractory celiac disease) treatable by a gluten-free diet, after some length of time on a gluten-free diet when the antibodies to gluten epitopes have cleared and when the intestinal mucosa has sufficiently healed, it may be possible to reprogram the immune system to tolerate gluten through fecal transplantation, along with vitamin D supplementation, providing a new healthy gut bacteria mix.  One problem, however, is that in many cases the damage to the intestinal mucosa from celiac disease does not entirely heal.[9,10]  This means that a long-term or permanent state of increased intestinal permeablity or "leaky gut" exists after beginning a gluten-free diet.  "Leaky-gut" is by no means a benign condition.  It puts a strain on the liver's detoxification abilities having to continually deal with toxins readily passing through the "leaky" intestinal mucosa.  The toxins come from gut bacteria as well as from drugs and environmental chemicals including household products and cosmetics.  Inhaled environmental toxins can be ingested when mucus expelled from the lungs is swallowed.  The overload on the liver and its inability to keep up with detoxification can lead to long-term debilitating medical conditions such as wide-spread chronic pain, muscle pain and weakness, neuropathies, fatigue, dry mouth, frequent urination, swelling, allergies, and even to other autoimmune disorders[11] due to fat soluble toxins accumulating in adipose tissue where they remain causing inflammation and raising havoc indefinitely.  The result is an unfavorable pro-inflammatory immune system environment which could impede any chance of restoring gluten tolerance.

    A promising treatment that could entirely heal the intestinal mucosa and "leaky gut" is a treatment based on a novel protein called R-spondin1.  Prior to January 2009 a small San Francisco pharmaceutical company, Nuvelo, was developing an R-spondin1 therapy drug with the designation, NU206.  NU206 had shown some great promise and success in lab studies.  Dramatic mucosal healing was demonstrated in an experimental colitis model with mice.[12]  Nuvelo's first targets were to use NU206 to heal and reduce intestinal mucosal damage from cancer chemotherapy and radiation therapy and to treat short-bowel syndrome.  In December 2008 Nuvelo had actually announced results from Phase 1 clinical safety trials on 32 healthy male volunteers demonstrating administration of NU206 caused no adverse effects.[13]  Unfortunately, Nuvelo, which also has other drugs in development, ran short of funding and, in January 2009, merged with a Colorado company, ARCA biopharma.[14]  ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. [Open Original Shared Link]  It appears that all NU206 research and development and clinical trials were suspended with the merger.  NU206, an extremely promising drug that might enable full intestinal mucosal healing and recovery in celiac disease now sits idly on a shelf with no indication clinical trials will ever resume.  While there has been some very limited research on R-spondin1 in other medical applications by other scientists, there has been no new R-spondin1 research on intestinal healing since the merger.  Any celiac disease interest group with access to funding for celiac disease research should consider contacting ARCA biopharma to see what efforts might be implemented to restart this very important R-spondin1 research.

    Sources:

    1. More Evidence Links Gut Bacteria to Celiac Disease
    Roy S. Jamron
    Celiac.com 2008 Nov 6.

    2. Do Vitamin D Deficiency, Gut Bacteria, and Gluten Combine in Infancy to Cause Celiac Disease?
    Roy S. Jamron
    Celiac.com 2008 Jun 16.

    3. Fecal Transfer Proves Potent Clostridium difficile Treatment
    Jenni Laidman
    Medscape Medical News 2013 Jan 16.
    Open Original Shared Link

    4. Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
    Els van Nood, Anne Vrieze, Max Nieuwdorp, Susana Fuentes, Erwin G. Zoetendal, Willem M. de Vos, Caroline E. Visser, Ed J. Kuijper, Joep F.W.M. Bartelsman, Jan G.P. Tijssen, Peter Speelman, Marcel G.W. Dijkgraaf, Josbert J. Keller
    NEJM 2013 Jan 16; Published Online
    Open Original Shared Link

    5. C difficile: Synthetic Stool Substitute Clears Infection
    Jenni Laidman
    Medscape Medical News 2013 Jan 10.
    Open Original Shared Link

    6. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: "RePOOPulating" the gut
    Elaine O Petrof, Gregory B Gloor, Stephen J Vanner, Scott J Weese, David Carter, Michelle C Daigneault, Eric M Brown, Kathleen Schroeter and Emma Allen-Vercoe
    Microbiome 2013 Jan 9;1:3.
    Open Original Shared Link

    7. Molecular mimicry revisited: gut bacteria and multiple sclerosis.
    Westall FC.
    J Clin Microbiol. 2006 Jun;44(6):2099-104.
    Open Original Shared Link

    8. IgA cross-reactivity between a nuclear autoantigen and wheat proteins suggests molecular mimicry as a possible pathomechanism in celiac disease.
    Natter S, Granditsch G, Reichel GL, Baghestanian M, Valent P, Elfman L, Gronlund H, Kraft D, Valenta R.
    Eur J Immunol. 2001 Mar;31(3):918-28.
    Open Original Shared Link

    9. Mucosal healing and mortality in coeliac disease.
    Lebwohl B, Granath F, Ekbom A, Montgomery SM, Murray JA, Rubio-Tapia A, Green PH, Ludvigsson JF.
    Aliment Pharmacol Ther. 2013 Feb;37(3):332-9.
    Open Original Shared Link

    10. Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet.
    Lanzini A, Lanzarotto F, Villanacci V, Mora A, Bertolazzi S, Turini D, Carella G, Malagoli A, Ferrante G, Cesana BM, Ricci C.
    Aliment Pharmacol Ther. 2009 Jun 15;29(12):1299-308.
    Open Original Shared Link

    11. Chemical-induced allergy and autoimmunity
    Marty Bernardus Franciscus Wulferink
    [s.l.] : [s.n.], 2001 - Tekst. - Proefschrift Universiteit Utrecht
    Open Original Shared Link

    12. R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice.
    Zhao J, de Vera J, Narushima S, Beck EX, Palencia S, Shinkawa P, Kim KA, Liu Y, Levy MD, Berg DJ, Abo A, Funk WD.
    Gastroenterology. 2007 Apr;132(4):1331-43.
    Open Original Shared Link

    13. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
    2008 Dec 10.
    Open Original Shared Link

    14. Biotechs Arca, Nuvelo complete reverse merger
    2009 Jan 28.
    Open Original Shared Link



    User Feedback

    Recommended Comments

    Guest Michele

    Posted

    Great article. I had some serious health problems after giving birth to my daughter which lead to 8 months of C. Dificile. After finally getting rid of C Dif, I continued to experience health problems (severe allergy symptoms, skin rashes, infections like strep throat, pneumonia). When my medical doctors came up short, I went to a homeopath who told me I had a wheat allergy. I went on a gluten-free diet and my health problems went away. I had considered the poop transplant when I couldn't get rid of C Dif so I find it really interesting that there is a potential connection between the poop transplant and celiac. Please keep providing articles on this subject.

    Link to comment
    Share on other sites
    Guest Touscents

    Posted

    Interesting to me because I have celiac disease and a fatty liver. No previous explanation for the fatty liver, as I am not a drinker.

    Link to comment
    Share on other sites
    Guest Dan

    Very interesting read, even though I have been gluten-free for more than five years my gut is still not totally right and I am susceptible to any gut bug that is going around. This may be the answer to my prayers in a weird kind of way.

    Link to comment
    Share on other sites
    Guest Kirke

    Very helpful, well researched and written.

    I am pleased to be able to pass it on to people I know with these and similar issues.

    I'm sure it will make a difference.

    Many Thanks.

    Link to comment
    Share on other sites


    Guest
    This is now closed for further comments

  • Get Celiac.com Updates:
    Help Celiac.com:
    Donate
  • About Me

    Roy Jamron

    Roy S. Jamron holds a B.S. in Physics from the University of Michigan and an M.S. in Engineering Applied Science from the University of California at Davis, and independently investigates the latest research on celiac disease and related disorders.


  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):





    Celiac.com Sponsors (A17-M):




  • Related Articles

    Scott Adams
    Nature Immunology 2, 353 - 360 (April 2001)
    Celiac.com 04/12/2001 - According to an article published in the April issue of Nature Immunology, Dr. Marc Rothenberg and colleagues at the Childrens Hospital Medical Center in Cincinnati, Ohio performed a series of experiments on mice which led them to the conclusion that white blood cells called eosinophils could be the cause of many food allergies and gastrointestinal inflammation. The researchers believe that the eosinophil cells, which are present throughout the body, mistakenly identify food proteins as germs in individuals with food allergies. When the intestinal lining of an allergic person is exposed to an allergen, a substance called eotaxin is released by the cells lining the intestine, which causes the eosinophil cells...


    Scott Adams
    Arch Dis Child 2004;89:499-501,512-515.
    Celiac.com 09/12/2004 – According to a recent study by Italian researchers, about 1% of Italian schoolchildren have celiac disease. The scientists screened blood samples taken from 3,188 schoolchildren aged 6 to 12 years for the presence of tissue Transglutaminase (tTG). The results showed that 33 tested positive for tTG, and of those 30 were verified by follow-up biopsies, and 3 refused biopsies but also tested positive for celiac disease-related antibodies and celiac disease-associated HLA DQ2-8. Out of the 33 who tested positive only 12 had symptoms.
    The researchers believe that the subsequent treatment of these children will likely help them to avoid future autoimmune disorders associated with untreated celiac disease. They a...


    Destiny Stone
    Celiac.com 07/26/2010 - There is very little information currently available regarding the effects of follow up strategies for those celiac patients that follow a gluten-free diet. Therefore, it was the aim of of researchers in Italy to determine the t-transglutaminase antibodies (t-TG) in celiac disease patients while they were enrolled in a community based follow-up program over a 5-year period.
    Most patients that are diagnosed with celiac disease are told they need to adhere to a gluten-free diet for the remainder of their lives, and then they are usually left to figure it out on their own. However, it is recommended that celiac patients have regularly scheduled  follow-ups after diagnosis for early detection of celiac related complications, and to reinforce the importance of adhering ...


    Jefferson Adams
    Celiac.com 07/03/2013 - Researchers have completed a genetic study of six autoimmune diseases, including diabetes, the largest such study of human disease genetics to date. The study will help scientists in their efforts to uncover the causes of these diseases, which include autoimmune thyroid disease, celiac disease, Crohn’s disease, psoriasis, multiple sclerosis and type 1 diabetes.
    While currently unknown, the underlying causes of these conditions are believed to involve a complex combination of genetic and environmental factors. In each of the six diseases, the identified genetic variants explained only a proportion of the heritability.
    Under one of the current major genetic disease hypotheses, the so called ‘rare-variant synthetic genome-wide association hypothesis,’ a sma...


  • Recent Activity

    1. - CatherineWang replied to B1rdL0ver's topic in Related Issues & Disorders
      40

      Dealing with constant nausea and just feeling awful.

    2. - cristiana replied to BunnyBrown's topic in Related Issues & Disorders
      3

      Recently had my esophagus dilated

    3. - cristiana replied to twe0708's topic in Post Diagnosis, Recovery & Treatment of Celiac Disease
      54

      How Long Do Celiac Patients Live?

    4. - Exchange Students replied to Exchange Students's topic in Parents, Friends and Loved Ones of Celiacs
      2

      Exchange Students who are celiac in need of host

    5. - Scott Adams replied to Exchange Students's topic in Parents, Friends and Loved Ones of Celiacs
      2

      Exchange Students who are celiac in need of host


  • Celiac.com Sponsor (A19):



  • Member Statistics

    • Total Members
      120,160
    • Most Online (within 30 mins)
      7,748

    sandy32
    Newest Member
    sandy32
    Joined

  • Celiac.com Sponsor (A20):


  • Forum Statistics

    • Total Topics
      120.2k
    • Total Posts
      1m

  • Celiac.com Sponsor (A22):




  • Who's Online (See full list)


  • Celiac.com Sponsor (A21):



  • Popular Now

    • Sunflowers06
      6
    • Momkaren
      10
    • Elizabeth M Blair
      5
    • B1rdL0ver
    • twe0708
      54
  • Popular Articles

    • Scott Adams
    • Scott Adams
    • Scott Adams
    • Scott Adams
    • Scott Adams
  • Upcoming Events

×
×
  • Create New...